治疗olaparib期间的肝胆药物不良反应:对EudraVigilance报告系统数据的分析
Elena-Mirabela Velişcu1, Cecilia Cagnotta2,3, Maria Giuseppa Sullo2
1Eu2P Programme, University Bordeaux, Bordeaux, France.
Frontiers in drug safety and regulation
|January 26, 2026
概括
一种PARP抑制剂Olaparib与肝损伤有关. 对344例病例的分析显示,主要是细胞分解性损伤,有些病例与肝脏瘤有关,强调需要进一步进行安全研究.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
背景情况:
- 奥拉巴里布是一种用于BRCA突变瘤的Poly ADP-Ribose聚合酶 (PARP) 抑制剂.
- 肝毒性与olaparib有关,这是药监风险评估委员会注意到的.
研究的目的:
- 描述与olaparib相关的药物诱导性肝损伤 (DILI) 病例.
- 将这些DILI病例按肝损伤来源分层 (胆固醇,细胞分解,混合,肝脏相关的调查,未指明).
- 分析来自EudraVigilance (EV) 数据库的数据.
主要方法:
- 从EV数据库中检索了344个Olaparib诱导的肝损伤个体病例安全报告 (ICSR).
- 根据肝损伤来源分层分类的病例.
- 分析了人口统计数据和事件分类.
主要成果:
- 大多数病例涉及18-64岁的女性患者.
- 19.5%的DILI病例是细胞分解的,3.5%是胆固醇的,1.5%是混合的.
- 显著比例的病例与"肝脏相关的调查" (39.8%) 和肝脏瘤 (20.6%) 有关.
结论:
- 需要进行进一步的药监测研究,以充分评估olaparib的肝脏安全性.
- 了解olaparib诱导的肝损伤机制对于临床预防和管理至关重要.
相关概念视频
Data Reporting and Recording
5.4K
Reporting and recording are crucial in data documentation. The timely, thorough, and accurate documentation of facts is essential when recording patient data. Failure to record findings during an assessment or interpretation of a problem will result in loss of information and make the patient document unreliable. The reader is left with general impressions if the information is not specific. A recording is documenting data of the individual's health information in a traceable, secure, and...
5.4K
Allergic Drug Reactions
1.5K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.5K
Drug Metabolism: Phase I Reactions
4.8K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
4.8K
Drug Metabolism: Phase II Reactions
5.0K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
5.0K
Drugs for Treatment of Constipation-Predominant IBS
802
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
802
Drugs for Treatment of Ulcerative Colitis in IBD
497
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
497


